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The complexity of living cells is primarily determined by the genetic information encoded
in DNA and gets fully disclosed upon translation. A major determinant of complexity is
the reversible post-translational modification (PTM) of proteins, which generates variants
displaying distinct biological properties such as subcellular localization, enzymatic activity
and the ability to assemble in complexes. Decades of work on phosphorylation have
unambiguously proven this concept. In recent years, the covalent attachment of Ubiquitin
or Small Ubiquitin-like Modifiers (SUMO) to amino acid residues of target proteins has
been recognized as another crucial PTM, re-directing protein fate and protein-protein
interactions. This review focuses on the role of ubiquitylation and sumoylation in the
control of DNA damage response proteins. To lay the ground, we begin with a description
of ubiquitylation and sumoylation, providing established examples of DNA damage
response elements that are controlled through these PTMs. We then examine in detail
the role of PTMs in the cellular response to DNA double-strand breaks illustrating
hierarchy, cross-talk, synergism or antagonism between phosphorylation, ubiquitylation
and sumoylation. We conclude offering a perspective on Ubiquitin and SUMO pathways
as targets in cancer therapy.
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INTRODUCTION
The components of signal transduction pathways are organized in
a hierarchical manner and communicate with one another. In its
simplest formulation, a signaling pathway can be represented with
a linear cascade where unidirectional arrows connect a stimulus
to the final response through a defined number of intermedi-
ates. The recent sequencing of animal and plant genomes and
the advent of systems biology have changed this perspective.
Proteome scale interaction studies have unveiled the existence
of interfaces between pathways and shown that the multiplicity
of interactions among their components likely accounts for the
array of outputs observed in biological systems. While this novel
perspective represented per sè a step forward, it still had the intrin-
sic limitation of merely providing a static snapshot of biological
networks. The need for a more realistic picture of signal trans-
duction prompted the development of predictive modeling that,
by representing the dynamic flow of information, accounts for the
fluctuation of variables as it actually occurs in defined biological
systems (Barabasi and Oltvai, 2004). Despite their intrinsic limi-
tation though, “snapshots” provided by reductionist approaches
currently represent our best option to study and explain the
functioning of signal transduction networks at the molecular
level.
Considering that proteins are the constitutive elements of
cellular networks and they hierarchically relate to each other,
modification of structural or enzymatic traits of one or more ele-
ments in a network will necessary affect network properties and
result in outputs that are directly observable (i.e., cell prolifera-
tion in response to growth factors, cell cycle arrest or terminal
differentiation in response to antimitogens or differentiation
factors, respectively). Alteration of the properties of network
components is achieved through post-translational modifications
(PTM), consisting in the covalent addition of chemical groups to
one or more amino acids of a protein target in a manner that is,
in most cases, reversible. The hierarchical, synergistic or antag-
onistic combination of PTMs defines a code that translates into
distinct outputs.
HISTORICAL PERSPECTIVE
Ubiquitin entered the arena of scientific discoveries in the mid-
seventies as result of serendipity and pioneering work initiated
in the midst of more trendy studies addressing how the infor-
mation contained in DNA is decoded to generate the variety
of proteins that make up a cell (Ciechanover, 2009). Studies
aimed at elucidating the molecular mechanism of liver regen-
eration led to the identification of a non-histone chromosomal
protein, named A24, displaying physicochemical properties sim-
ilar to those of histones. The localization of A24 in nuclear and
nucleolar chromatin as well as its marked decrease upon nucleo-
lar hyperthrophy led to the suggestion that A24 might represent
a rDNA repressor (Goldknopf et al., 1975). Ciechanover and col-
leagues came to the discovery of Ubiquitin from another front.
Based on the concept that synthesis and destruction of cellu-
lar proteins are homeostatic, with a perfect equilibrium being
a necessary condition for life, they undertook studies on mech-
anisms of protein degradation. Using reticulocytes as model
system, that are known to get rid of lysosomes during terminal
differentiation but retain the ability of degrading hemoglobin,
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they set out to identify the non-lysosomal mechanism of pro-
tein degradation present in these cells. Using classic biochemical
protocols consisting of chromatographic fractionation of crude
cell extracts followed by reconstitution of the enzymatic activity
of interest through complementation of fractions, they discov-
ered that proteolysis occurs through a cascade of events culmi-
nating in the covalent addition of a heat-stable component to
proteins targets. Such component was named ATP-dependent
proteolysis factor 1 (APF-1) and is now known as Ubiquitin
(Ciehanover et al., 1978). Protein modification by APF-1, in
turn, was shown to facilitate selective target recognition by the
proteolytic machinery (Hershko et al., 1980). The subsequent
discovery of several Ubiquitin-like proteins (UBLs) helped shed-
ding light on the complexity of this PTM. UBLs were essen-
tially demonstrated to have functions other than the control of
protein degradation. This is the case of the “Small Ubiquitin-
like Modifier”, in short SUMO, which was identified as a PTM
of RanGAP (Matunis et al., 1996; Mahajan et al., 1997), the
activator of the GTPase Ran that controls shuttling of cargos
across the nuclear membrane. Sumoylation was shown to facil-
itate association of RanGAP with the nuclear envelope (Mahajan
et al., 1998). Other notable examples are NEDD8, which can
be covalently linked to cullins (Hori et al., 1999), the scaffold
components of multisubunit Ubiquitin E3-ligases, in a man-
ner that affects their activity; ISG15, which is conjugated to
target proteins upon IFNα/β-induced viral response or inflam-
mation (Jeon et al., 2010; Zhao et al., 2013); Urm1, which has
low sequence homology to Ubiquitin (Goehring et al., 2003),
though it displays a similar fold and is involved in oxidative
stress responses in yeast; and, finally, the Atg cascade control-
ling autophagy in yeast and man, which is the main mech-
anism responsible for the degradation of cellular components
in response to nutrients starvation. This consists of the E1-
like enzyme Atg7, the E2-like components Atg3 and Atg7, and
the E3-like Atg12-Atg5 conjugate that facilitates transfer of the
Ubiquitin-like modifier Atg8 to phospholipids (Hanada et al.,
2007).
UBIQUITYLATION
Ubiquitin is a highly conserved regulatory protein of 76 amino
acids (8.5 kDa), which is constitutively expressed in all tissues of
eukaryotic organisms. In mammalian cells, Ubiquitin is encoded
by 4 genes: RSP27A, UBA52, UBB, and UBC (Kimura and
Tanaka, 2010). The ATP-dependent conjugation of Ubiquitin
C-terminal glycine (G76) to lysine residues in the substrate
leads to the formation of an isopeptide bond. Ubiquitin itself
contains seven lysines behaving as acceptors for additional
Ubiquitin molecules to generate poly-chains. Ubiquitylation is
carried out in a cascade of reactions: first, a thiolester bond
is formed in an ATP-dependent manner between a cysteine in
the active site of the E1-activating enzyme and Ubiquitin G76.
Second, Ubiquitin is transferred to the active cysteine of an
E2-conjugating enzyme. Finally, an E3-ligase enzyme binds the
E2-Ub complex and transfers Ubiquitin to lysine residues of the
acceptor substrate (Hershko and Ciechanover, 1998) (Figure 1).
Mammalian cells express only 2 E1s, approximately 38 E2s and
more than 600 E3s.
E2-CONJUGATING ENZYMES
E2-conjugting enzymes can be classified in 17 subfamilies
(Michelle et al., 2009) characterized by an active core called
UBC (Ubiquitin-conjugating) domain. Ubiquitin E2 enzymes are
structurally similar to UBL modifiers E2s, though the former can
specifically interact with the two E1s involved in ubiquitylation
(Ye and Rape, 2009). Each E2 enzyme can interact with multi-
ple E3s, as demonstrated for Cdc34 (E2) and SCF complexes (E3)
(Skowyra et al., 1997) or the UBE2C/UBE2S (E2s) and the APC/C
(anaphase promoting complex/cyclosome; E3) (Williamson et al.,
2009) or as shown in network interaction studies (Markson et al.,
2009). Specificity is provided by the N-terminal region of the
E2 where the amino acidic sequence determines the secondary
structure of loops (L1 and L2) that contact two loops and an
α-helix of the E3 (Zheng et al., 2000). For E2s interacting with
more than one E3, the residue involved in recognition usually dif-
fers from one E3 to the other (Zhang et al., 2005a). The binding
affinity between Ubiquitin-charged E2s and their cognate E3s is
generally high, rendering very fast the kinetic of interaction (Das
et al., 2009). Moreover, binding sites for E1 and the specific E3
often overlap in the E2, such that the E2 must dissociate from
the E3 to be charged with Ubiquitin by the E1 and vice-versa
(Eletr et al., 2005). E2 enzymes catalyze Ubiquitin chains initi-
ation and elongation. Whereas some of them, such as UBE2W
and UBE2E in humans, are specifically used by their E3 BRCA1
for chain initiation, the heterodimeric complex UBE2N-UBE2V1
and UBE2K are mainly involved in chain elongation (Christensen
et al., 2007; Rodrigo-Brenni and Morgan, 2007; Jin et al., 2008b).
Few E2s can mediate both processes, as illustrated by yeast Cdc34
that, together with SCF, is responsible for initiating Ubiquitin
chains formation on Sic1 (cell cycle inhibitor subunit of cyclin-
dependent kinase 1) in a non-interacting manner and for chain
elongation by direct interaction with the substrate (Petroski and
Deshaies, 2005).
E3-LIGASES
E3s are often part of multimeric complexes and can be divided
in two main classes: HECT (Homologous to E6AP COOH-
terminus) and RING (Really Interesting New Gene). A cysteine in
HECT E3s catalytic domain bindsUbiquitin and transfers it to the
substrate in an E2-independent manner (Kulathu and Komander,
2012) (Figure 1). The C-terminal domain of HECT E3s is highly
conserved and retains both catalytic activity and the determi-
nants for chain type specificity (You and Pickart, 2001), while
the N-terminal region determines substrate specificity (Huang
et al., 1999). Established members of the HECT family are
E6AP, a partner of the oncogenic E6 protein of human papillo-
mavirus, responsible for p53 downregulation (Huang et al., 1999),
Itch/AIP4, with roles in the inflammatory signaling pathways
(Chastagner et al., 2006) and Nedd4 and Nedd4L that partici-
pate in the development of mouse central nervous system (Kumar
et al., 1992).
The vast majority of E3-ligases known to date belongs to
the RING family and is characterized by the presence of the
Cys/His-rich RING finger domain. The RING finger brings in
close proximity substrate and activated E2 enzyme, with the
latter directly transferring Ubiquitin to the former (Figure 1).
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FIGURE 1 | Simplified scheme of ubiquitylation. The ubiquitylation
cascade initiates with an ATP-dependent reaction consisting in the
formation of a thiolester bond between a cysteine in the active site of
the E1-activating enzyme and G76 in Ubiquitin (Ub). Next, Ubiquitin is
transferred to the active cysteine of an E2-conjugating enzyme that
interacts with an E3-ligase. The latter can either directly transfer
Ubiquitin to lysine residues of the acceptor substrate, as is the case
for HECT-E3s, or recruit substrates to the E2 enzyme, a mechanism
that characterizes RING-E3s. Finally, ubiquitylated substrates are shuttled
to the 26S proteasome and Ubiquitin is recycled for another round of
reactions. DUBs oppose substrate degradation by reversing the process
of ubiquitylation.
A domain structurally related to the RING finger, the U-box, is
found in many E3 ligases of this class (Deshaies and Joazeiro,
2009). Rad18 was the first identified RING domain-containing
protein and, together with the E2-conjugating enzyme Rad6, was
shown to be essential for post-replicative bypass of UV-induced
DNA damage in yeast (Bailly et al., 1997). The RING domain,
along with a B-box (zinc-binding fold similar to the RING) and
a coiled-coil region (CC), collectively called RBCC supradomain,
characterizes the 80 members of the TRIM (Tripartite Interaction
Motif) family of E3-ligases (Marin, 2012). A small subfamily of
E3 ligases is characterized by the presence of three RING domains:
an N-terminal (N-RING), a in-between (IBR) and a C-terminal
(RING2 or C-RING) (Eisenhaber et al., 2007). Parkin, a protein
involved in Parkinson’s disease, is the best-characterized mem-
ber of this subfamily (Chaugule et al., 2011). The Cullin/RING
Ubiquitin ligase (CRL) subfamily represents the largest subgroup
of the RING-finger E3 ligases (Deshaies and Joazeiro, 2009). CRLs
are multisubunit E3s composed of a RING finger domain pro-
tein (Rbx1 or Rbx2) responsible for recruiting the ubiquitylated
E2 enzyme, a scaffold protein member of the Cullin family and
a receptor for substrate recognition (F-box protein). Some CRLs
additionally feature a linker protein, such as Skp1 in the SCF
complex or CRL1 and DDB1 in the CRL4 complex (Deshaies
and Joazeiro, 2009). CRLs are activated by a PTM consisting
in conjugation of NEDD8 to the Cullin component (Pan et al.,
2004).
ATYPICAL UBIQUITIN CHAINS
Ubiquitylation indicates the process of single Ubiquitin moiety
addition to a substrate as well as its extension to form Ubiquitin
polymers. Chain extension can occur at all seven lysine residues
present on Ubiquitin (K6, K11, K27, K29, K33, K48, K63) (Ikeda and
Dikic, 2008). E2s such as UBE2N (UBC13) or UBE2RI (CDC34)
show specificity for linkage to K63or K48, respectively (Vandemark
et al., 2001; Petroski and Deshaies, 2005). Others, like UBE2D
and UBE2E, can promote different types of Ubiquitin chains
formation (Kim et al., 2007). K48 and K63 linked chains repre-
sent the two mostly studied modifications by Ubiquitin, with the
first essentially involved in degradation by the 26S proteasome
(Komander and Rape, 2012) and the second mainly affecting
the function of signaling components (Sun and Chen, 2004) and
DNA repair proteins (Chen and Sun, 2009). Proteins undergoing
degradation are recognized by the substrate receptor component
of the 26S proteasome only if they contain chains longer than
four Ubiquitin moieties (Thrower et al., 2000). The processiv-
ity of such chains, which is the number of Ubiquitin moieties
attached to a protein or to a growing Ubiquitin chain while it
is associated to the E3 ligase, determines the rate of substrate
degradation (Rape et al., 2006). K6-linked chains do not likely
have a proteolytic role (Kim et al., 2011). K11-linkage, on the
contrary, plays a key role in the degradation of cell cycle regu-
lators as well as in endoplasmic reticulum associated degradation
(ERAD) andmembrane trafficking (Behrends and Harper, 2011).
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Little is known about the relatively low abundant K27-, K29-
and K33-linkages (Komander and Rape, 2012). An additional
type of Ubiquitin chain assembly was recently discovered, the
so-called LUBAC (Linear Ubiquitin Chains Assembly Complex),
which is formed by a complex of two E3 RING-finger ligases,
HOIL-1L and HOIP. This type of linkage is characterized by
head-to-tail assembly, in which the C-terminal glycine of the pre-
vious Ubiquitin is linked to the methionine residue of the next
Ubiquitin. Linearly-linked Ubiquitin chains are mainly involved
in targeting proteins with a role in innate and adaptive immune
signaling pathways (Walczak et al., 2012). Finally, evidence for
the presence of more than one linkage type in the same poly-
Ubiquitin chain has been provided (Kim et al., 2007). Mixed
Ubiquitin chains were shown to result from the activity of the
RING finger proteins Ring1B and Bmi1. The latter are com-
ponents of the Polycomb repressive complex 1 (PRC1), with
Ring1B displaying E3-ligase activity toward histone H2A. Mono-
ubiquitylation of H2Awas shown to depend, at least in vitro, from
self-ubiquitylation of Ring1B through the generation of atypical
mixed K6-, K27-, and K48-based chains on the same Ubiquitin
molecule (Ben-Saadon et al., 2006).
DEUBIQUITYLATING ENZYMES
Ubiquitylation is a reversible process, with deUbiquitinases
(DUBs) being responsible for the disassembly of Ubiquitin
chains (Nijman et al., 2005). Deubiquitylation controls cell cycle
transitions, proteasome- and lysosome-dependent degradation
pathways, DNA repair, endocytosis and signal transduction path-
ways among others. Importantly, DUBs participate in control-
ling the dynamic state of histone ubiquitylation. An essential
function played by DUBs is the co-translational activation of
Ubiquitin, which is expressed as fusion to ribosomal proteins
or in linear poly-Ubiquitin chains (Reyes-Turcu et al., 2009).
A second important function is the recycling of free Ubiquitin
from unattached chains (Komander et al., 2009). The human
genome encodes approximately 100 DUBs, distinguished in five
families: Ubiquitin C-terminal hydrolases (UCH), Ubiquitin spe-
cific proteases (USP/UBP), ovarian tumor (OUT), Josephines
and JAB1/MPN/Mov34 metalloenzymes (JAMM) (Reyes-Turcu
et al., 2009). Whereas the first four families behave as cysteine
proteases, JAMM function as zinc-dependent metalloproteases.
To prevent inappropriate or unscheduled cleavage of substrates,
DUBs activity is controlled by a variety of PTMs, including
phosphorylation, ubiquitylation and sumoylation (Reyes-Turcu
et al., 2009). Besides the catalytic domain, DUBs feature protein-
protein interaction domains and Ubiquitin-binding domains that
facilitate formation of multimeric complexes and interaction
with substrates, respectively. In most cases, binding to Ubiquitin
causes DUBs to undergo conformational changes that expose
the catalytic site, which is often hidden by a loop or a larger
domain (Reyes-Turcu et al., 2009). DUBs such as USP14, UCH37,
and POH1 are often found associated with the 19S subunit
of the proteasome, a feature that allows hydrolyzing the poly-
Ubiquitin chain from the substrate and recycling Ubiquitin prior
to channeling the target protein into the proteasome (Finley,
2009). Reactive oxygen species (ROS) reversibly inactivate Cys-
based DUBs, as exemplified by the key regulator of genomic
stability USP1, the oxidation of which facilitates PCNA mono-
ubiquitylation and the consecutive recruitment of Polη for the
repair of oxidation-induced lesions (Cotto-Rios et al., 2012).
SHUTTLING TO THE PROTEASOME
The destiny of proteins modified by K48 poly-Ubiquitin chains
is degradation by the 26S proteasome. In the DNA damage
response, this task is facilitated by shuttling orchestrated by ded-
icated receptor proteins such as yeast Rad23, Dsk2, Ddi1, and
the Shp1/Cdc48/p97 complex. Receptor proteins recognize poly-
Ubiquitin chains in their targets by virtue of Ubiquitin-Associated
(UBA) domains and interact with subunits of the proteasome
via Ubiquitin-Like (UBL) folds, thus effectively shuttling cargoes
to the proteasome (Grabbe and Dikic, 2009). The yeast Rad23,
which was originally identified for its role in nucleotide excision
repair (NER), and its human homologues hHR23A and hHR23B
are paradigmatic to this pathway. Rad23 contains two UBA and
anN-terminal UBL domain that dynamically interacts with either
one of the two UBA domains (Goh et al., 2008). Binding of an
UBA domain to poly-Ubiquitin chains of the cargo protein dis-
places the UBL domain that becomes available for interacting
with the proteosomal subunit 5a (Mueller and Feigon, 2003),
facilitating the delivery of cargos to the proteasome. Paradigmatic
is human p97 and its Ubiquitin-binding partner, the heterodimer
UFD1-NPL4, that are recruited to DNA lesions and selectively
remove K48-Ubiquitin conjugates allowing the subsequent depo-
sition of 53BP1, BRCA1, and Rad51 to regions undergoing repair
(Meerang et al., 2011).
SUMOYLATION
SUMO proteins and Ubiquitin have only limited sequence iden-
tity but they fold in a similar manner (Bayer et al., 1998). SUMO-
2 and SUMO-3 are 95% identical but display only 43% identity
to SUMO-1. SUMO proteins are generated as inactive precursors
and processed by Sentrin/SUMO-specific proteases (SENPs) that
catalyze the removal of a C-terminal oligopeptide, exposing the
glycine that is conjugated to lysine residues in the target (Xu and
Au, 2005).
SUMO CASCADE
As for Ubiquitin, SUMO-1, SUMO-2, and SUMO-3 are conju-
gated to substrates through a dedicated E1-E2-E3 cascade. SUMO
proteins bind the activating enzyme E1 [SAE1 and SAE2 in mam-
mals, (Gong et al., 1999)] in an ATP-dependent manner and are
transferred to the conjugating enzyme UBC9, which is the only
E2 dedicated to SUMO conjugation (Johnson and Blobel, 1997).
UBC9 is able to recognize and transfer SUMO to targets in the
absence of a co-adjuvating E3, though E3-like proteins containing
an SP-RING domain facilitate the process by enhancing the affin-
ity of UBC9 for its substrates (Bernier-Villamor et al., 2002). In
the absence of an E3, acetylation apparently provides a means for
UBC9 to discern between substrates carrying extended vs. regular
recognition motifs (see below) (Hsieh et al., 2013).
The distinct mechanism of SUMO recognition and conju-
gation likely depends on the different distribution of charged
residues on the surface of SUMO proteins as compared to
Ubiquitin (Melchior, 2000). Of the SUMOE3-ligases identified to
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date, some display exquisite specificity, such as RanBP2 that selec-
tively targets RanGAP1 and Sp100 (Pichler et al., 2002). Others,
like the PIAS family of proteins that are the mammalian homo-
logues of yeast Siz proteins, act as repressors of STAT3 (Chung
et al., 1997) and a number of transcription factors (Schmidt
and Muller, 2003). Similarly to RING Ubiquitin ligases, the
Siz/PIAS SUMO E3-ligases do not physically bind SUMO but
rather interact non-covalently with it. Furthermore, through their
zinc-binding SP-RING domain they associate with UBC9. In this
manner Siz/PIAS bring SUMO-loaded UBC9 in close proximity
to the protein target and facilitate transfer of the SUMO mojety
(Hochstrasser, 2001). Among other SP-RING type SUMO E3s,
TOPORS was the first reported example of an E3 ligase support-
ing the transfer of both Ubiquitin and SUMO (Rajendra et al.,
2004; Weger et al., 2005).
SUMO CHAINS
SUMO-2 and SUMO-3 can polymerize to form chains on protein
substrates whereas SUMO-1 is only added as monomer (Tatham
et al., 2001). It is established that some substrates are modified
either by SUMO1, namely RanGAP1 (Saitoh and Hinchey, 2000),
or SUMO2/3, namely PML, whereas others are modified indif-
ferently by both SUMO1 and SUMO2/3 (Vertegaal et al., 2006).
The reason for such heterogeneity in the SUMO conjugation pro-
cess is currently unknown, though it may be in part explained by
the different pools of SUMO proteins available in the cell, with
SUMO1 being mostly conjugated and SUMO2/3 forming a free
pool that is mobilized in response to environmental stress (Saitoh
and Hinchey, 2000).
The minimal core consensus sequence for recognition and
sumoylation of target proteins is defined as -K-X-D/E (with 
being a hydrophobic residue). An extended sumoylation motif
consisting in the sequence -K-X-D/E-X2-(E/D)4−5 may com-
prise sites of phosphorylation in the acidic stretch that follows the
sumoylated lysine (Yang et al., 2006).
The assembly of proteins complexes in response to sumoyla-
tion was addressed by means of two-hybrid screens that led to the
discovery of proteins bearing SUMO-interacting motifs (SIMs)
(Hannich et al., 2005).
DESUMOYLATING ENZYMES
As for other PTMs, sumoylation is a reversible process. The
enzymes reversing sumoylation belong to the class of SENP
proteins that control SUMOmaturation from precursor polypep-
tides. Of the six SENP enzymes present in the mammalian
genome, SENP1 and SENP2 display the ability of their yeast
counterpart Ulp1 to control both the maturation of SUMO pro-
teins and desumoylation reactions. SENP1 and SENP2 display
a slight preference for pre-SUMO1 or pre-SUMO2/3, respec-
tively, in the process of maturation but act equally well on both
during deconjugation (Xu and Au, 2005). SENP3 and SENP5
preferentially remove monomeric SUMO2/3 moieties, whereas
SENP6 and SENP7 selectively act on SUMO2/3 chains and do
not participate in the maturation of SUMOproteins (Mikolajczyk
et al., 2007). SENP enzymes are themselves controlled by sumoy-
lation, ubiquitylation and subcellular localization (Hickey et al.,
2012).
SUMO FUNCTION
The role of sumoylation at the organism level became appar-
ent thanks to studies in budding yeast showing that depletion
of Ubc9 causes cell cycle arrest at G2/M (Seufert et al., 1995).
Likewise, studies conducted in fission yeast showed that dele-
tion of the Ubc9 homologue hus5 is not lethal but results in
chromosome segregation defects (Al-Khodairy et al., 1995). Data
obtained from chicken DT-40 cells showed that Ubc9 is essential
for the viability of higher eukaryotic cells and its knockout results
in the formation of multiple nuclei, likely due to cytokinesis
defects, with a significant proportion of cells entering apopto-
sis (Hayashi et al., 2002). Studies conducted in mice confirmed
the severe phenotype of Ubc9 knockout, with embryonic lethality
observed at early post-implantation stage. Furthermore, blas-
tocysts failed to expand after 2 days in culture and displayed
defects in chromosome condensation and segregation as well as
dysmorphic nuclear envelopes and disruption of nucleoli and
PML bodies (Nacerddine et al., 2005). Sumoylation has also
been linked to human pathologies, in that human SUMO1 hap-
loinsufficiency was found to be responsible for cleft lip and
palate, a finding corroborated by a mouse model (Alkuraya
et al., 2006). Others, however, reported no obvious develop-
mental defects in SUMO1 knockout mice (Evdokimov et al.,
2008; Zhang et al., 2008), suggesting possible redundancy among
SUMO proteins.
THE SUMO ENIGMA
A peculiarity distinguishing SUMO from other PTMs is the abil-
ity of triggering fully-fledged responses despite a minor amount
of the proteins involved in the response is actually modified by
SUMO, a phenomenon denoted as “the SUMO enigma” (Hay,
2005). This occurs in transcriptional repression, where modifi-
cation by SUMO is apparently required for the recruitment of
transcription factors into repressive protein complexes, with their
sequestration remaining permanent even upon SUMO removal
(Wilkinson and Henley, 2010). SUMO modification of only a
small substrate population at any given time point was also
suggested to occur for DNA repair proteins such as thymidine-
DNA glycosylase (TDG). TDG is part of the base excision repair
system (BER) and displays the ability of specifically address-
ing uracil/thymidine base mismatches (Sancar et al., 2004). The
rate-limiting step in the enzymatic reaction carried out by TDG
is its dissociation from the abasic site (AP site) generated as
first step in the BER process. The high affinity of TDG for the
structure generated upon removal of the base is an important self-
protection mechanism put in place by the cell since AP sites can
turn into DNA strand breaks, thus threatening genome stability
(Hardeland et al., 2002). Sumoylation is the appropriate solu-
tion to this issue, in that SUMO-modified TDG looses affinity
for the abasic site allowing recruitment of the (AP)-endonuclease
that acts in the next step of BER (Sancar et al., 2004). To re-
initiate the circle, desumoylation by SENPs/ULPs renders TDG
promptly available for the next round of lesion recognition and
processing (Hardeland et al., 2002). Thus, SUMO modifica-
tion of minimal amounts of TDG is sufficient to address the
repair of uracil/thymidine base mismatches in a highly controlled
manner.
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PTMs IN DNA DAMAGE RESPONSE: THE OLD AND THE NEW
The cascade of events resulting from detection of DNA dam-
age and orchestrating its repair has been best described for DNA
double-strand breaks (DSBs). A detailed account of ubiquityla-
tion and sumoylation events occurring at DSBs will be followed
by a brief mention to the signaling triggered by other types of
DNA lesions.
DSB RECOGNITION
Initial players consist of proteins or proteins complexes such as
Ku70 and Ku80 or MRE11/RAD50/NBS1 (MRN) that, through
recognition and binding to DNA ends, facilitate recruitment and
activation of the protein kinases DNA-PKcs or ATM, respectively.
The latter function as transducers of the DNA damage signal and
help coordinating repair with checkpoint activation and cell cycle
arrest (Sancar et al., 2004). When the sister chromatid is available
as template, repair is addressed through the error-free pathway
of homologous recombination (HR) rather than the predomi-
nant but error-prone pathway of non-homologous end-joining
(NHEJ) (Sancar et al., 2004). HR initiates upon recognition of
DNA ends by the MRN complex, an event that facilitates recruit-
ment of ATM through direct interaction with the C-terminus of
the NBS1 component (Falck et al., 2005) (Figure 2A).
ATM is an homodimer and exists in a complex containing the
protein phosphatase PP2A, which maintains ATM inactive by cat-
alyzing its constitutive dephosphorylation (Goodarzi et al., 2004),
and the histone acetyltransferase Tip60, which is maintained at
low level by CUL3-dependent ubiquitylation and plays a role in
the modification of chromatin at sites of damage (Murr et al.,
2006; Sun et al., 2009). NBS1-dependent ATM recruitment at sites
of damage is followed by ATM autophosphorylation at S1981 with
ensuing activation of the kinase.
The mechanism of DSB repair operating in the absence of a
homologous template for recombination-mediated repair is non-
homologous end joining. In this case, DNA ends are bound
by the Ku70/Ku80 heterodimer that recruits DNA-PK catalytic
subunit, causing inward translocation of the heterodimer and
positioning the catalytic subunit at DNA ends. Next, depend-
ing on the complexity of the lesion, different processing factors
are recruited, such as the endonuclease Artemis and the polynu-
cleotide kinase/phosphatase PNKP. The release of DNA-PKcs
from DNA ends, which is induced by autophosphorylation, leads
to the final step of the process, with XRCC4, DNA ligase IV and
XLF performing ligation of the DNA ends (Dobbs et al., 2010).
SITE MARKING
ATM-mediated phosphorylation of H2AX at the C-terminal S139
(γH2AX) (Rogakou et al., 1998), possibly paralleled by dephos-
phorylation of Y142 (Cook et al., 2009), marks the site of damage
and contributes to destabilize nucleosome structure (Figure 2A).
A critical role in the generation of γH2AX in response to IR
is apparently played by mono-ubiquitylation of the histone at
K119/K120, which facilitates the subsequent recruitment of ATM.
H2AX mono-ubiquitylation is catalyzed by a complex composed
of the polycomb protein BMI1 and the RING finger proteins
RING1 and RNF2 (Ginjala et al., 2011; Pan et al., 2011; Wu
et al., 2011). Upon phosphorylation, H2AX acts as docking site
for MDC1 that, by virtue of the high affinity of its C-terminal
BRCT tandem repeats for the phospho-S139 epitope in γH2AX,
is the first protein localizing at sites of damage (Bekker-Jensen
and Mailand, 2010). MDC1 orchestrates the consecutive assem-
bly of factors that will, in turn, mediate the recruitment of DNA
repair proteins. Such factors comprise 53BP1, BRCA1, and the
E3-Ubiquitin ligase RNF8. Through its N-terminal FHA domain
RNF8 binds phosphorylated MDC1 as well as HERC2, with the
latter acting as coordinator of Ubiquitin-dependent assembly of
DNA repair factors (Bekker-Jensen et al., 2010). SUMO1 modifi-
cation of HERC2 and RNF168 by the E3-ligase PIAS4 promotes
recruitment of RNF8 to the complex and stabilizes the interaction
between RNF8 and the E2-conjugating enzyme Ubc13 (Danielsen
et al., 2012). In turn, RNF8 contributes to remodel chromatin
around sites of damage through a transient K48 and a persistent
K63 ubiquitylation of both H2A and H2AX (Huen et al., 2007;
Mailand et al., 2007). Histone ubiquitylation was long known as
a post-translation modification occurring during transcriptional
responses and mono-ubiquitylation of H2A in the context of the
cellular response to DNAdamage was first described for the repair
of UV-induced lesions (Bergink et al., 2006). RNF8 was identified
as the E3-ligase catalyzing H2A and H2B mono-ubiquitylation
in response to IR (Wu et al., 2009) and UV (Marteijn et al.,
2009) and thus proposed to be a conserved element in the
initial response to DNA DSBs and UV lesions. H2A ubiquityla-
tion contributes to the recruitment of DNA repair factors. Once
bound to DNA, MDC1 is sumoylated at K1840 by PIAS4 in a
manner that facilitates its recognition and ubiquitylation by the
E3-ligase RNF4, with consequent degradation (Luo et al., 2012).
Additional factors recruited to phosphorylated H2AX consist of
chromatin remodeling complexes such as INO80 and SWR1 in
yeast (Morrison et al., 2004; Van Attikum et al., 2007) and p400 in
humans (Xu et al., 2010). K63 histone di-ubiquitylation by RNF8,
in turn, allows binding of the adaptor protein RAP80 through its
UIM motifs (Sato et al., 2009) and the recruitment of Abraxas
(ABRA1), which acts as anchor for BRCA1 at sites of DNA dam-
age (Sobhian et al., 2007; Bekker-Jensen and Mailand, 2010). The
BRCA1 complex, in turn, contains the DUB BRCC36, which is
able to depolymerize K63 Ubiquitin chains, thus contributing to
maintain steady-state levels of Ubiquitin at sites of damage (Shao
et al., 2009).
It has been proposed that initial histone ubiquitylation by
RNF8 represents a docking signal for RNF168, a second E3-
Ubiquitin ligase that is recruited to chromatin to the purpose of
amplifying the signal through further ubiquitylation of histones
around the site of damage (Doil et al., 2009; Pinato et al., 2009;
Stewart et al., 2009). Structural studies on the RING domains
of RNF8 and RNF168 supported this view showing that RNF8
can dimerize and as such productively interact with Ubc13/Mms2
and catalyze K63-linked poly-Ubiquitin chains, whereas the
monomeric RNF168 does not interact with the E2 enzyme and is
by far catalytically less efficient (Campbell et al., 2012). RNF168
features two MIUs (Motif Interacting with Ubiquitin) that are
responsible for recognition of di-ubiquitylated K63 on histone
H2As and accrual at sites of damage (Doil et al., 2009; Pinato et al.,
2009; Stewart et al., 2009). Deletion of the two MIU-domains
showed that a small fraction of RNF168 was nonetheless able
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FIGURE 2 | Proximal and widespread DNA damage signals. (A) In
response to the generation of DSBs, ATM is recruited to DNA in
an MRN-dependent manner and is activated by autophosphorylation.
ATM-dependent phosphorylation of H2AX triggers the recruitment of
factors that mark the site of damage and cooperate to amplify the
signal. In addition, ATM phosphorylates proteins that contribute to
remodel chromatin and promote homologous recombination (see text
for details). (B) Activation of ATM triggers the phosphorylation of
the protein kinase CHK2 among others, which freely diffuses from
the site of damage to transduce DNA damage signals to cell cycle
regulators, resulting in the inhibition of cell cycle transitions (see
text for details).
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to bind chromatin (Pinato et al., 2009), leading to the discovery
of an additional Ubiquitin-binding domain (UIM- and MIU-
related) that is necessary for proper localization of RNF168 at
sites of damage (Pinato et al., 2011). A twist to the debate on the
hierarchy of E3s recruitment at sites of damage was brought by
studies showing that RNF8 is primarily responsible for ubiqui-
tylation of histone H2As at C-terminal sites (K118/K119), whereas
RNF168 catalyzes themono-ubiquitylation of a set of sites located
at the N-terminus of histone H2As (K13/K15) (Gatti et al., 2012;
Mattiroli et al., 2012). This finding indicated that the order by
which E3s are recruited does not predict the order in which they
ubiquitylate H2As. The authors suggested that RNF168 might
catalyze the priming event at N-terminal sites that, being located
on the opposite side of the nucleosome with respect to the RNF8
target sites, may initiate distinct signaling events (Mattiroli et al.,
2012).
The importance of RNF8-/RNF168-dependent ubiquitylation
is well exemplified by the RIDDLE syndrome, where recessive
mutations in the RNF168 gene lead to the expression of aber-
rant RNF168 protein isoforms, resulting in failure of 53BP1 and
BRCA1 accumulation at IR-induced foci and of the subsequent
activation of DNA damage responses (Stewart et al., 2009).
Sumoylation of RNF8, RNF168, and BRCA1 mediated by
PIAS1 and PIAS4 enhances their E3-ligase activity, contribut-
ing to render more efficient histone ubiquitylation at DSBs
(Galanty et al., 2009). Through interaction with the Ubiquitin-
conjugating UBE2L6/UBCH8, RNF8 controls the degradation of
the demethylase JMJD2A/KDM4A resulting in the uncovering
of H4K20me2 mark and promoting the recruitment of 53BP1
at DNA damage sites (Mallette et al., 2012). RAD18 is another
Ubiquitin E3-ligase recruited at DNA lesions through recogni-
tion of K63 ubiquitylated histones and acting downstream of
RNF8/RNF168 (Huang et al., 2009).
The boost of DNA damage-induced ubiquitylation events was
initially shown to be modulated by deubiquitylating enzymes
such as USP3, BRCC36, and OTUB1 (Nicassio et al., 2007; Shao
et al., 2009; Nakada et al., 2010). Subsequent studies on mech-
anisms that control the excessive spreading of histone ubiquity-
lation around sites of damage demonstrated the involvement of
the HECT-domain E3-ligases TRIP12 and UBR5. By determin-
ing the amount of RNF168 that is loaded at sites of damage,
TRIP12 and UBR5 contribute to optimize the recruitment of
physiological amounts of genome caretakers such as 53BP1 and
BRCA1 (Gudjonsson et al., 2012). An RNF168 paralog, namely
the E3-ligase RNF169, also contributes to limit the spreading of
non-proteolytic ubiquitylation at regions flanking DNA damage
sites. Specifically, RNF169 MIU2 domain was demonstrated to
recognize histones ubiquitylated by RNF8/RNF168, thus outcom-
peting and limiting the productive recruitment of 53BP1 and
RAP80 (Chen et al., 2012; Poulsen et al., 2012). Recognition
of Ubiquitin by RNF168 and RNF169 is mediated by modules
composed of a UBD juxtaposed to a short targeting sequence,
called the LR-motif (LRM), a structure also shared by RAD18 and
RAP80 (Panier et al., 2012).
In concomitance with the events described above, phosphory-
lation of MDC1 by casein kinase 2 (CK2) allows the former to
capture additional molecules of ATM that phosphorylate both
H2AX in the neighboring nucleosomes and MDC1 itself (Polo
and Jackson, 2011). Phosphorylation does not only serve the
function of promoting the assembly of DNA repair modules, but
also contributes to break up interactions to facilitate repair pro-
cesses. This is the case of the transcriptional repressor and RING
finger protein KAP1/TIF1β/TRIM28, which is released from chro-
matin upon ATM-mediated phosphorylation of S824, an event
that results in the dissociation of heterochromatin protein 1
(HP1) from chromatin and contributes to remodel regions that
will undergo repair (Goodarzi et al., 2008). Chromatin relaxation
in response to DSBs apparently consists of two stages: an early
step that occurs before the generation of γH2AX and that is ATP-
dependent (Kruhlak et al., 2006) and a second step that relies on
the recruitment of a fraction of the RNF20/RNF40 heterodimer
to sites of damage where it catalyzes the mono-ubiquitylation of
H2B (Moyal et al., 2011). Mechanistically, it was demonstrated
that mono-ubiquitylation of H2B is sufficient to interfere with
the compaction of chromatin (Fierz et al., 2011).
DNA END RESECTION
Marking DNA double-strand break sites is followed by the
recruitment of repair proteins in charge of processing DNA ends
to create structures that are suitable to recombination. This task
is initially accomplished by the MRN complex that in conjunc-
tion with CtIP/RBBP8 carries out initial trimming at the break,
a step that is followed by extensive processing of DNA ends
by the redundant function of EXO1 and the DNA2/BLM com-
plex (Mimitou and Symington, 2009; Eid et al., 2010). Proteins
participating in DNA processing are also controlled by PTMs.
CtIP is phosphorylated in a CDK-dependent manner in S
and G2 phases of the cell cycle at T847 and S327. Whereas phos-
phorylation of the former affects resection activity, modification
of the latter influences BRCA1 binding (Yu and Chen, 2004;
Huertas and Jackson, 2009). In response to DSBs CtIP is addi-
tionally phosphorylated by ATM (Matsuoka et al., 2007). Binding
of BRCA1/BARD1 to CtIP is mediated by the BRCT domain of
BRCA1 and causes ubiquitylation of CtIP in a manner that does
not target it to degradation but facilitates binding to DNA and
enrichment at sites of damage (Yu et al., 2006). This is an exam-
ple of ubiquitylation as means to selectively target protein to a
defined region in the cell or to a structure.
In response to stalled replication, EXO1 protein level
is controlled by ATR-dependent phosphorylation and poly-
ubiquitylation catalyzed by a currently unknown E3 ligase (El-
Shemerly et al., 2005, 2008). On the other hand, both in yeast
andman EXO1 nuclease activity is controlled by PIKK-dependent
phosphorylation upon induction of DSBs (Morin et al., 2008;
Bolderson et al., 2010). Sumoylation of EXO1 has also been
reported (Tatham et al., 2011), though its functional significance
awaits clarification.
The Bloom syndrome helicase (BLM) plays an important role
in homologous recombination and in the repair of damaged repli-
cation forks (Jones and Petermann, 2012). Modification of BLM
by SUMO is necessary for a balanced γH2AX response in HU
treated cells, with cells that express SUMO-deficient forms of
BLMdisplaying excessive γH2AX phosphorylation, accumulation
of DNA breaks and hypersensitivity to DNA damage (Ouyang
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et al., 2009). In HU-treated cells expressing SUMO-deficient
forms of BLM, the ability to localize RAD51 at damaged replica-
tion forks is compromised and sister-chromatid exchanges does
not occur. This led to the suggestion that sumoylation represents
a switch between pro- and anti-recombinogenic roles for BLM in
HR (Ouyang et al., 2009).
Resection of DNA ends by EXO1 or the BLM/DNA2 complex
leads to the formation of long 3′-overhangs that are the structures
participating in homologous recombination. Replication Protein
A (RPA) is the major ssDNA binding protein complex present in
eukaryotes and consists of three subunits: RPA1 (70 kDa), RPA2
(32 kDa), and RPA3 (14 kDa). RPA1 has high affinity for DNA
and is the docking subunit for a number of proteins involved
in DNA synthesis and repair (Fanning et al., 2006). RPA2 has
lower affinity for DNA and, thanks to its C-terminal winged helix
domain, binds weakly but specifically to AID, to BER proteins
such as UDG or to NER proteins such as XPA (Fanning et al.,
2006). RPA2 is the major target of phosphorylation events that
occur during DNA replication and the DNA damage response.
RPA3 is the only component with no affinity for DNA but playing
an important role in the stabilization of the trimeric protein com-
plex (Fanning et al., 2006). It has been observed that association
between the SUMO protease SENP6 and RPA1 during transi-
tion through S-phasemaintains RPA1 in a hypo-sumoylated state.
Camptothecin-induced DSBs weaken the interaction between
RPA1 and SENP6, facilitating RPA1 sumoylation at K449 andK577,
an event that results in increased interaction with Rad51 and
displacement of RPA from the ssDNA filament (Dou et al., 2010).
Sumoylation of MRE11 and RAD54 has also been reported
(Tatham et al., 2011), though the functional significance of this
PTM is as yet unknown.
PROXIMAL AND DISTAL SIGNALING
In addition to the two members of the PIKK family of pro-
tein kinases mentioned above in the context of DSB recognition,
namely ATM and DNA-PK, also ATR participates in orches-
trating the overall response to genotoxic damage. An important
component of the DNA damage response is the transduction
of signals to the cell cycle machinery. Unlike ATM or DNA-
PK that are activated by DNA ends (Uematsu et al., 2007; You
et al., 2007), ATR activation specifically depends on the pres-
ence of ssDNA resulting from the processing of different types of
damage (Zou and Elledge, 2003) or naturally occurring at repli-
cation forks (MacDougall et al., 2007). ATR triggering typically
occurs after ATM activation (Jazayeri et al., 2006). Two check-
point kinases are phosphorylated by ATR at S317 and S345 (CHK1)
(Zhao and Piwnica-Worms, 2001) and by ATM or ATR at seven
residues in the N-terminal domain (CHK2) (Matsuoka et al.,
2000), respectively. This triggers homo-dimerization of the check-
point kinases and full activation through auto-phosphorylation
(Lee and Chung, 2001) (Figure 2B).
The ATR-CHK1 pathway controls the timing of DNA repli-
cation origin firing during regular transition through S-phase
(Shechter et al., 2004) and triggers G2/M arrest in response to
γ-irradiation (Liu et al., 2000). ATR-mediated phosphorylation
of CHK1 at S345 exposes a degron-like region at the C-terminus
of the kinase allowing recognition by cytoplasmic Cul1/FBX6
or nuclear Cul4A/CDT2 SCF E3-ligase complexes that promote
poly-ubiquitylation and degradation of CHK1 (Zhang et al., 2009;
Huh and Piwnica-Worms, 2013). It has been proposed that pro-
teolysis of activated CHK1 results in checkpoint termination
(Zhang et al., 2005b).
The ATM/CHK2 axis controls both transient and sustained
cell cycle arrest following detection of DNA damage (Figure 2B)
(Shiloh and Ziv, 2013). Namely, by phosphorylating CDC25
phosphatases and the WEE1 kinase, CHK2 blocks cell cycle tran-
sitions mediated by Cyclin-CDKs, whereas by phosphorylating
p53, MDM2, and PML it promotes apoptosis (Antoni et al.,
2007).
Both CHK1 and CHK2 impinge on the machinery driving cell
cycle transitions by directly phosphorylating controllers of cyclin-
dependent kinases such as theWEE1 kinase and the CDC25A and
CDC25C phosphatases (Bartek et al., 2004) (Figure 2B). WEE1
catalyzes phosphorylation of two residues in the Gly-rich P-loop
of CDK1, namely T14, and Y15, in a manner that does not affect
nucleotide binding but hampers catalysis (Ferrari, 2006). CDC25
phosphatases specifically remove the phosphate from the two
residues in the ATP-binding site of CDKs, causing full activation
of Cyclin/CDK complexes (Ferrari, 2006). Inhibition of CDC25C
by DNA damage essentially occurs by a 14-3-3-mediated seques-
tration mechanism, whereas CDC25A degradation via Ubiquitin-
proteasome pathways is a primary control mechanism both in
dividing cells and in response to DNA damage (Donzelli and
Draetta, 2003). Phosphorylation of CDC25A on S76 by CHK1 (Jin
et al., 2008a) serves as priming event to facilitate phosphorylation
on S79 and S82 by protein kinase CK1 or glycogen synthase kinase-
3β (GSK-3β) (Kang et al., 2008; Honaker and Piwnica-Worms,
2010). This, in turn, allows recruitment of the SCFβ−TrcP E3 ligase
that promotes CDC25A poly-ubiquitylation (Busino et al., 2003).
DNA DAMAGE RECOVERY
Following completion of DNA repair, cell cycle restart is con-
tributed by degradation of molecules that were involved both in
signaling DNA damage and in blocking cell cycle progression.
This is the case of the adaptor protein Claspin, which is targeted
by SCF-βTrcP upon PLK1-dependent phosphorylation (Mamely
et al., 2006; Peschiaroli et al., 2006) and whose level is maintained
low throughout G1 by the APC/CDH1 E3-ligase (Bassermann
et al., 2008), and of the kinase WEE1 (Bartek and Lukas, 2007).
OTHER DNA LESIONS
Additional examples of regulation of DNA damage responses by
ubiquitylation are provided by Fanconi Anemia (FA), Translesion
DNA Synthesis (TLS) and Nucleotide Excision Repair (NER).
FA is an X-linked disease characterized by mutations in genes
coding for factors of this DNA repair pathway. Upon expo-
sure to DNA interstrand cross-linking (ICL) agents, FANC pro-
teins form a nuclear “core-complex” in which FANCL is the E3
Ubiquitin ligase responsible, together with its cognate E2 UBE2T,
for the mono-ubiquitylation of FANCI and FANCD2 (the ID-
complex) on residues K561 and K523, respectively. This is an
event required for the formation of damage-induced foci (Wang,
2007). Mutation of the Ubiquitin-binding domain on FANCI-
FANCD2 results in hypersensitivity to mitomycin C or cisplatin
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(Smogorzewska et al., 2007). In TLS, which represents one of
the main mechanisms allowing DNA lesion bypass in S-phase
(Waters et al., 2009), ubiquitylation of PCNA plays a key role (see
below). BER addresses the repair of modified bases or abasic sites
resulting from depurination/depyrimidination events (Almeida
and Sobol, 2007). In addition to TDG, which participates in
lesion recognition and processing, the BER scaffold component
XRCC1 is controlled by phosphorylation (Loizou et al., 2004)
and sumoylation (Gocke et al., 2005). The E3-ligase CHIP/STUB1
adds another layer of control to BER by mediating ubiquitylation
of the pool of XRCC1 and Polβ that are not directly participat-
ing in the process of lesion recognition and repair (Parsons et al.,
2008).
INTERDEPENDENCE OF PTMs
HIERARCHICAL PRIMING
An interesting feature of PTMs is their reciprocal influence, as
clearly established for histones, where the antagonism or the
synergism of certain modifications defines a “code” that guides
protein-DNA interactions (Sims and Reinberg, 2008). These,
in turn, influence the compaction of chromatin and ultimately
affect biological responses such as transcription, DNA replica-
tion and DNA repair (Kouzarides, 2007). Such effects can be
cumulative or exclusive, with a clearly defined hierarchy of PTMs
affecting a given target protein. In the DNA damage response a
notable example of consecutive PTMs occurring in a hierarchical
manner is represented by FEN1, the flap endonuclease respon-
sible for cleavage of single stranded 5′ overhangs in Okazaki
fragments during DNA replication and also involved in DNA
repair. Phosphorylation at S187 in FEN1 catalytic domain by
cyclin A/CDK2 results in its release from PCNA, the DNA poly-
merase processivity factor that stimulates FEN1 nuclease activity
(Henneke et al., 2003). Subsequent modification of K168 in FEN1
by SUMO3 facilitates K354 ubiquitylation by the E3 ligase PRP19,
resulting in FEN1 degradation at the end of S-phase, an event that
contributes to ensure a timely transition to G2 (Guo et al., 2012).
COMPETITION FOR THE SUBSTRATE
In addition to the ability of sumoylation to directly alter the prop-
erties of the protein undergoing this modification, it may also
serve as a competitor to other PTMs. Indeed, since sumoylation
targets lysine residues in the substrate, similarly to ubiquity-
lation, methylation or acetylation, the modification of one or
more lysine in the substrate could block other PTM machiner-
ies from accessing these residues, thus indirectly affecting protein
function (Walsh et al., 2005). Established examples of compe-
tition among PTMs are RanGAP1, which upon sumoylation
preferentially binds the nuclear pore complex (Melchior, 2000),
the NF-κB signaling pathway (Huang et al., 2003) and PCNA
(Hoege et al., 2002). Specifically to the latter, early studies showed
that mono-ubiquitylation mediated by RAD6 (E2) and RAD18
(E3), K63 poly-ubiquitylation by MMS2, UBC13, and RAD5
and sumoylation by UBC9 all affect the same lysine residue
(K164) (Hoege et al., 2002). Subsequent work clearly established
that PCNA mono-ubiquitylation supports translesion synthesis,
a pathway allowing stalled DNA replication to proceed beyond
damage through the replacement of processive polymerases with
specialized polymerases (Bienko et al., 2005; Garg and Burgers,
2005). K63 poly-ubiquitylation, on the other hand, facilitates syn-
thesis by a template-switch mechanism, a complex but essentially
error-free pathway that utilizes the undamaged, newly synthesized
daughter strand of the sister chromosome as template (Branzei
and Foiani, 2010). Finally, PCNA sumoylation prevents the for-
mation of DSBs and the occurrence of inappropriate recombi-
nation events at stalled DNA replication forks by a mechanism
involving the anti-ricombinogenic activity of the helicase Srs2 in
yeast (Papouli et al., 2005; Pfander et al., 2005) and possibly by a
similar mechanism in humans (Gali et al., 2012).
CROSS-TALKING
A number of Ubiquitin E3-ligases display the ability to bind
SUMO chains on proteins that, in turn, become their sub-
strates. A reported case is PML, which undergoes modifica-
tion by SUMO-1 as well as by SUMO-2/3. Whereas attachment
of SUMO-1 determines confinement of the protein in PML
nuclear bodies (Muller et al., 1998) formation of SUMO2/3
chains facilitates the recruitment of the E3-ligase RNF4, which
ubiquitylates the SUMO chains and ultimately targets PML to
degradation (Lallemand-Breitenbach et al., 2008; Tatham et al.,
2008; Weisshaar et al., 2008). RNF4 displays the ability to inter-
act with other sumoylated substrates, such as MDC1 and RPA,
via its N-terminal SUMO interaction motif (SIM) and to sub-
sequently regulate their stability (Galanty et al., 2012). Another
interesting case is BRCA1, which co-localizes with and is sumoy-
lated by PIAS1 and PIAS4 at sites of damage. This, in turn, was
reported to enhance BRCA1 E3-ligase activity possibly through a
SUMO-dependent increase of the E3-E2 interface (Morris et al.,
2009).
SYNERGY
The advent of proteome-wide studies allowed appreciating the
fact that, like phosphorylation, sumoylation triggered by a
defined stimulus or stress does not target a single components but
a vast majority of the protein machinery involved in the response.
Work conducted in yeast established that lack of overall sumoyla-
tion in a hypomorphic mutant of the SUMO E2 Ubc9 impaired
survival in response to DNA damage (Cremona et al., 2012).
This resulted from incomplete replication of damaged DNA as
well as defective resection at DSBs. The authors found that DNA
damage-induced sumoylation occurred independently of phos-
phorylation events that were triggered by the checkpoint and was
proposed to act in parallel with them to support cell survival
(Cremona et al., 2012). A study conducted using SILAC-based
mass spectrometry identified 844 different SUMO conjugates,
the abundance of which did not seem to change in response to
DNA damage (Psakhye and Jentsch, 2012). Interestingly though,
the set of sumoylated proteins enriched in response to DNA
damage was specifically that of the HR machinery. The authors
found that DNA end resection and the consecutive generation
of long ssDNA tracts acted as trigger to the wave of sumoylation
that characterized the response. Sumoylation of HR proteins was
found to occur independently and in parallel, with no influence
of one sumoylation event on the other, and to entirely depend
on the SUMO E3-ligase Siz2. Sumoylation promoted physical
Frontiers in Genetics | Cancer Genetics June 2013 | Volume 4 | Article 106 | 10
Bologna and Ferrari Post-translational modifications in the DNA damage response
interaction among HR proteins, thus facilitating DNA repair
(Psakhye and Jentsch, 2012).
UBIQUITIN AND SUMO AS TARGETS IN CANCER THERAPY
Ubiquitylation and/or sumoylation defects have been implicated
in the pathogenesis of a number of human diseases among which
is cancer (Sun, 2006; Bettermann et al., 2012).
UBIQUITIN AND CANCER
Examples of over-expression of ubiquitylation pathway compo-
nents in cancer cells are the p53-specific ARF-BP1/Mule HECT
E3-ligase, the F-box proteins SKP2 and β-TrcP1, the SCF com-
ponent Cul-4A and the RING-finger proteins RNF11, ZNF164
(Chen et al., 2006), and RNF5 (Bromberg et al., 2007). Mutation
or deletion of E3-ligases that normally function as tumor suppres-
sors has also been reported. This is the case of the RING-finger
E3-ligases BRCA1/BARD1 and SIAH1 (Chen et al., 2006). Finally,
epigenetic inactivation of genes coding for the E3-ligase HACE1
(Hibi et al., 2008) or the RING-finger protein CHFR (Chen et al.,
2006) has been observed in several types of carcinomas.
Based on the reasoning that E3 enzymes are druggable tar-
gets, pharmaceutical companies embarked on high-throughput
screenings in search for compounds that would target the active
site of E3-ligases or block interaction with their substrates (Sun,
2006; Hoeller and Dikic, 2009). A notable example of the latter
is Nutlin, which impairs the p53-HDM2 interaction by filling a
groove in HDM2 where p53 is accommodated (Vassilev, 2007).
Despite the initial enthusiasm raised by Nutlin and its deriva-
tives, the limitation of its efficacy in cells expressing wild-type
p53 excluded their use from a number of other cancers. More dis-
couraging, the cytostatic effect of Nutlins in p53-deficient cells
indicated that they did not solely inhibit the p53/HDM2 inter-
action (Vanderborght et al., 2006). The p53-targeting molecule
RITA (NSC652287), identified in a screening conducted on a pair
of isogenic cell lines differing only in their p53 status, was shown
to bind p53 N-terminus (Issaeva et al., 2004). However, RITA did
not specifically target the p53-HDM2 dimer but also other p53
protein complexes (Hjerpe and Rodriguez, 2008). Similar issues
were encountered with other inhibitors of E3-ligases (Guedat and
Colland, 2007).
Another interesting case of targeting E3-ligases is BRCA1.
Synthetic lethality was observed when PARP-inhibitors are
administered to cells of BRCA-deficient patients (Bryant et al.,
2005; Farmer et al., 2005). Considering that BRCA deficiency
occurs in <5% of breast cancers, the results obtained with
PARP-inhibitors prompted studies attempting to exploit the con-
cept of synthetic lethality in non-mutation carriers. Specifically,
small molecules targeting the phospho-dependent interaction of
BRCA1with partners such as Abraxas were administered to breast
and cervical cancer cells to mimic the inactivating mutation of the
otherwise wild-type BRCA1 gene. The data showed that, under
these conditions, PARP-inhibitors effectively sensitized cells to
IR-induced damage (Pessetto et al., 2012).
The E1-activating enzyme and the proteasome have also been
considered as possible targets, with the caveat that inhibiting
the ubiquitylation cascade at its apex may impair pathways
of vital importance to the survival of normal cells. This is
particularly true if one considers the widespread use of ubiquity-
lation in the control of cellular functions. Nonetheless, inhibitors
of the chymotryptic activity of the proteasome have been iden-
tified and characterized. Compounds such as bortezomib have
received approval from FDA and are currently used for the treat-
ment of multiple myeloma and mantle cell lymphoma (Guedat
and Colland, 2007; Rastogi and Mishra, 2012). Similarly, ATP-
competitive inhibitors blocking the transfer of Ubiquitin from
the E1-activating enzyme to E2-conjugating components of the
cascade have been identified (Guedat and Colland, 2007).
Inhibition of deubiquitylating enzymes has also been explored
as possible alternative to the development of inhibitors of the
ubiquitylation cascade. A compound specifically targeting USP7
was shown to stabilize p53, activate p53-dependent transcription,
block cell growth and induce apopotosis (Guedat and Colland,
2007). Recently, a novel strategy based on the use of combinato-
rial libraries of Ubiquitin variants has led to the identification of
mechanisms of DUBs inhibition and provided the demonstration
that this approach could be applied to the discovery of specific E2
or E3 inhibitors (Ernst et al., 2013).
SUMO AND CANCER
With regard to the role of SUMO in cancer, Ubc9/UBE2I was
found overexpressed in ovarian carcinoma specimens (Mo et al.,
2005). Xenografts studies conducted in mice revealed that tumors
expressing wildtype Ubc9 grew better than controls, while tumors
expressing dominant negative Ubc9 exhibited reduced growth
(Mo et al., 2005). A comprehensive study reported an increase
in UBC9 expression in primary colon and prostate cancer com-
pared with their normal tissue counterparts, whereas UBC9 levels
were found lower in metastatic breast, prostate, and lung can-
cer in comparison with their corresponding normal and primary
adenocarcinoma tissues (Moschos et al., 2010). Increased UBC9
expression was also observed in melanoma-infiltrated lymph
nodes, with depletion of UBC9 resulting in sensitization of
melanomas to the cytotoxic effects of topotecan and cisplatin
(Moschos et al., 2007). A comprehensive collection of studies on
UBC9 mRNA expression pattern in different cancer types can
be found at www.nextbio.com. Based on these findings, target-
ing UBC9 in cancer therapy was initially proposed (Mo et al.,
2005). However, given the widespread use of sumoylation as PTM
controlling numerous metabolic pathways, altering the overall
pattern of sumoylation in the cell was countered by others as
a non-specific and ineffective method to combat cancer (Bawa-
Khalfe and Yeh, 2010). Support to arguments in favor of UBC9
as valid target in cancer therapy is provided by its pattern of dif-
ferential expression, with higher levels of UBC9 in cancerous vs.
normal tissues, offering a possible therapeutic window (Mo and
Moschos, 2005). In this respect, crystallographic studies mapping
the surfaces in UBC9 involved in the interaction with specific E3s
and their substrates represent a promising avenue to the design of
small compounds disrupting selective sumoylation reactions (Mo
and Moschos, 2005).
Increased levels of the desumoylating enzyme SENP1 were
reported in thyroid oncocytic adenocarcinoma (Jacques et al.,
2005) and prostate cancer (Cheng et al., 2006). A transgenic mice
model showed that overexpression of Senp1 in the prostate led
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to the development of prostatic intraepithelial neoplasia at an
early age (Cheng et al., 2006). Promising results have been
obtained in studies aiming at the identification of SUMO-specific
protease (SENP) inhibitors (Hemelaar et al., 2004; Borodovsky
et al., 2005) or based on the screening of cysteine-protease
inhibitor libraries (Albrow et al., 2011). The latter, in particu-
lar, led to the identification of two classes of compounds: the
first, containing a reactive aza-epoxide electrophile linked to an
extended peptide backbone and the second, containing an acy-
loxymethyl ketone reactive group. Structure-activity relationship
studies led to the design of covalent inhibitors of multiple hSENPs
displaying micromolar IC50 values (Albrow et al., 2011).
Arsenic trioxide, which induces differentiation of leukemic
blasts and clinical remission, was shown to promote
SUMO-dependent poly-ubiquitylation of PML-RARα by the
Ubiquitin E3-ligase RNF4, with consequent degradation of the
fusion protein responsible for acute promyelocytic leukemia
(Lallemand-Breitenbach et al., 2008; Tatham et al., 2008). Thus,
in addition to classic approaches based on the chemical inhibition
of enzymatic activity, the case of arsenic trioxide illustrated that
among the variety of possible avenues to inhibit function, the
exploitation of existing pathways in the cell that may be triggered
at will is an important option.
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